Stock Research for BCRX

BCRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BCRX Stock Chart & Research Data

The BCRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BCRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BCRX Due diligence Resources & Stock Charts

The BCRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BCRX Detailed Price Forecast - CNN Money CNN View BCRX Detailed Summary - Google Finance
Yahoo View BCRX Detailed Summary - Yahoo! Finance Zacks View BCRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BCRX Trends & Analysis - Trade-Ideas Barrons View BCRX Major Holders - Barrons
NASDAQ View BCRX Call Transcripts - NASDAQ Seeking View BCRX Breaking News & Analysis - Seeking Alpha
Spotlight View BCRX Annual Report - CompanySpotlight.com OTC Report View BCRX OTC Short Report - OTCShortReport.com
TradeKing View BCRX Fundamentals - TradeKing Charts View BCRX SEC Filings - Bar Chart
WSJ View Historical Prices for BCRX - The WSJ Morningstar View Performance/Total Return for BCRX - Morningstar
MarketWatch View the Analyst Estimates for BCRX - MarketWatch CNBC View the Earnings History for BCRX - CNBC
StockMarketWatch View the BCRX Earnings - StockMarketWatch MacroAxis View BCRX Buy or Sell Recommendations - MacroAxis
Bullish View the BCRX Bullish Patterns - American Bulls Short Pains View BCRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BCRX Stock Mentions - StockTwits PennyStocks View BCRX Stock Mentions - PennyStockTweets
Twitter View BCRX Stock Mentions - Twitter Invest Hub View BCRX Investment Forum News - Investor Hub
Yahoo View BCRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BCRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BCRX - SECform4.com Insider Cow View Insider Transactions for BCRX - Insider Cow
CNBC View BCRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BCRX - OTC Markets
Yahoo View Insider Transactions for BCRX - Yahoo! Finance NASDAQ View Institutional Holdings for BCRX - NASDAQ


Stock Charts

FinViz View BCRX Stock Insight & Charts - FinViz.com StockCharts View BCRX Investment Charts - StockCharts.com
BarChart View BCRX Stock Overview & Charts - BarChart Trading View View BCRX User Generated Charts - Trading View




Latest Financial News for BCRX


BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever
Posted on Monday September 17, 2018

BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever. Yellow fever represents a significant unmet medical need and a new potential use of galidesivir. With this additional $3.5 million contract amendment, the NIAID development contract for galidesivir now totals $43.0 million.


What Sarepta Therapeutics’ Valuation Trend Indicates
Posted on Thursday September 13, 2018

Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.


Here's Why BioCryst Pharmaceuticals Rose 21.3% in August
Posted on Monday September 10, 2018

Believe it or not, share prices rose after the company announced a share offering.


RTP pharma scores $35M contract to supply CDC
Posted on Thursday September 06, 2018

Research Triangle Park-based pharma just scored what could be a $35 million contract to manufacture influenza treatments.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.